Naureen Keric
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naureen Keric has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Florian Ringel
Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, Germany
14 shared publications Florian Ringel
Department of Neurosurgery, University Medical Center Mainz, Johannes Gutenberg University of Mainz, Mainz, Germany
9 shared publications- Harald Krenzlin
Department of Neurosurgery, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany
8 shared publications Alf Giese
Department of Neurosurgery, University Medical Centre of theJohannes Gutenberg University of Mainz, Mainz, Germany
7 shared publications- Julia Masomi-Bornwasser
Department of Neurosurgery, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany
7 shared publications Harald Krenzlin
Department of Neurosurgery, University Medical Center Mainz, Johannes Gutenberg University of Mainz, Mainz, Germany
6 shared publications
Latest Publications
- Open Access
- 10 September 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 175 (3) , 967-977
Physician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT)
Purpose: Patients diagnosed with high-grade gliomas (HGG) often experience substantial psychosocial dis-tress. However, due to neurological and neurocognitive deficits its assessment remains challenging, and needs remain unmet. We compared a novel face-to-face assessment during doctor-patient conversations with questionnaire-based screening. Methods: In this multicenter, two-arm cluster-randomized study involving 13 centers patients in the interven-tion group (IG) were screened for distress via physician-patient conversations, while the control group (CG) completed the Distress Thermometer. Primary outcome was the proportion of patients with poor emotional functioning (measured with the EORTC Quality of Life Questionnaire) who received specialized psychosocial care (PC) within 3 months. Data were collected via patient and physician reports and medical records. Analysis employed mixed models logistic regression. Results: In total, 763 patients were enrolled at baseline, and 506 completed the follow-up. The emotional functioning was poor in 302/506 (59.7%). The frequency of patients reporting PC utilization was comparable between groups (IG 93/168, 55.4% vs. CG 87/134, 64.9%, odds ratio (OR) =0.67, 95% confidence interval (CI)=0.40-1.11, p=0.115). Likewise, the provision of information about special-ized psycho-oncological care was similar (IG 112/168, 66.7% vs. CG 94/134, 70.1%, OR=0.95, 95%CI=0.39-2.29, p=0.904). Conclusion: Physician-led, face-to-face distress screening was not superior to questionnaire-based screening in facilitating psychosocial care referrals. Nonetheless, it represents a feasible and patient-centered alternative, particularly for patients with high-grade gliomas suffering from neurocognitive or func-tional deficits.
- 10 September 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 175 (3) , 967-977
Open AccessPhysician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT)
Purpose: Patients diagnosed with high-grade gliomas (HGG) often experience substantial psychosocial dis-tress. However, due to neurological and neurocognitive deficits its assessment remains challenging, and needs remain unmet. We compared a novel face-to-face assessment during doctor-patient conversations with questionnaire-based screening. Methods: In this multicenter, two-arm cluster-randomized study involving 13 centers patients in the interven-tion group (IG) were screened for distress via physician-patient conversations, while the control group (CG) completed the Distress Thermometer. Primary outcome was the proportion of patients with poor emotional functioning (measured with the EORTC Quality of Life Questionnaire) who received specialized psychosocial care (PC) within 3 months. Data were collected via patient and physician reports and medical records. Analysis employed mixed models logistic regression. Results: In total, 763 patients were enrolled at baseline, and 506 completed the follow-up. The emotional functioning was poor in 302/506 (59.7%). The frequency of patients reporting PC utilization was comparable between groups (IG 93/168, 55.4% vs. CG 87/134, 64.9%, odds ratio (OR) =0.67, 95% confidence interval (CI)=0.40-1.11, p=0.115). Likewise, the provision of information about special-ized psycho-oncological care was similar (IG 112/168, 66.7% vs. CG 94/134, 70.1%, OR=0.95, 95%CI=0.39-2.29, p=0.904). Conclusion: Physician-led, face-to-face distress screening was not superior to questionnaire-based screening in facilitating psychosocial care referrals. Nonetheless, it represents a feasible and patient-centered alternative, particularly for patients with high-grade gliomas suffering from neurocognitive or func-tional deficits.
- Open Access
- 31 July 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (8) , 1-11
Distress screening in patients with high-grade glioma: diagnostic accuracy in relation to a structured clinical interview in a multicenter cluster-randomized controlled trial
Purpose: Structured clinical interviews, such as the Structured Clinical Interview for DSM (SCID), are considered the gold standard for diagnosing mental disorders but are challenging in routine clinical use due to their length. Therefore, screening instruments to identify the need for further assessment are required. The National Comprehensive Cancer Network Distress Thermometer (DT) screens for psychological distress, while the Emotional Functioning (EF) scale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) assesses emotional functioning. Both are frequently used in clinical routine. Additionally, three brief screening questions (TSQ), specifically developed for patients with glioma and integrated into doctor–patient consultations, may also be used for screening. This study aimed to evaluate the ability of the three tools to identify patients with psychiatric comorbidities as diagnosed by the SCID. Methods: Using data from glioma patients treated at 13 German hospitals participating in a cluster-randomized trial, discriminative abilities were assessed using receiver operating characteristic (ROC) curves and corresponding areas under the curve (AUCs). Confidence intervals (CIs) were estimated, and hypothesis tests were conducted using bootstrapping. Results: Of the 691 patients interviewed, 31% presented with at least one mental disorder. The EF scale demonstrated the best discriminative ability (AUC 0.70, 95% CI: 0.66–0.74), followed by the DT (AUC 0.69, 95% CI: 0.62–0.76), and the TSQ total score (AUC 0.61, 95% CI: 0.55–0.66). Conclusion: While all three tools performed better than random chance, none demonstrated convincing discriminative ability in identifying psychiatric comorbidities. In practice, screening tools can identify a substantial proportion of patients with mental disorders, however at the cost of a considerable number of false negatives.
- 31 July 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (8) , 1-11
Open AccessDistress screening in patients with high-grade glioma: diagnostic accuracy in relation to a structured clinical interview in a multicenter cluster-randomized controlled trial
Purpose: Structured clinical interviews, such as the Structured Clinical Interview for DSM (SCID), are considered the gold standard for diagnosing mental disorders but are challenging in routine clinical use due to their length. Therefore, screening instruments to identify the need for further assessment are required. The National Comprehensive Cancer Network Distress Thermometer (DT) screens for psychological distress, while the Emotional Functioning (EF) scale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) assesses emotional functioning. Both are frequently used in clinical routine. Additionally, three brief screening questions (TSQ), specifically developed for patients with glioma and integrated into doctor–patient consultations, may also be used for screening. This study aimed to evaluate the ability of the three tools to identify patients with psychiatric comorbidities as diagnosed by the SCID. Methods: Using data from glioma patients treated at 13 German hospitals participating in a cluster-randomized trial, discriminative abilities were assessed using receiver operating characteristic (ROC) curves and corresponding areas under the curve (AUCs). Confidence intervals (CIs) were estimated, and hypothesis tests were conducted using bootstrapping. Results: Of the 691 patients interviewed, 31% presented with at least one mental disorder. The EF scale demonstrated the best discriminative ability (AUC 0.70, 95% CI: 0.66–0.74), followed by the DT (AUC 0.69, 95% CI: 0.62–0.76), and the TSQ total score (AUC 0.61, 95% CI: 0.55–0.66). Conclusion: While all three tools performed better than random chance, none demonstrated convincing discriminative ability in identifying psychiatric comorbidities. In practice, screening tools can identify a substantial proportion of patients with mental disorders, however at the cost of a considerable number of false negatives.
- Open Access
Frequency and clinical associations of common mental disorders in adults with high‐grade glioma—A multicenter study
Background: One third of adults with cancer suffer from common mental disorders in addition to their malignant disease. However, it is unknown whether this proportion is the same in patients who have brain tumors and which factors modulate the risk for psychiatric comorbidity.Methods: In a multicenter study, patients with high‐grade glioma at 13 neurooncology clinics were enrolled consecutively and interviewed with the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (SCID) to diagnose common mental disorders. Predictors of psychiatric comorbidity were investigated using binary logistic regression.Results: Six hundred ninety‐one patients were interviewed. The proportion of patients who had mental disorders was 31% (95% confidence interval [CI], 28%–35%). There was evidence for an association of psychiatric comorbidity with the following factors: younger age (odds ratio [OR], 1.9; 95% CI, 1.1–3.4; p = .04), stable disease versus complete remission (OR, 1.7; 95% CI, 1.1–2.8; p = .04), lower income (OR, 1.7; 95% CI, 1.0–2.8; p = .04), living alone (OR, 1.6; 95% CI, 1.0–2.6; p = .05), fatigue (OR, 1.6; 95% CI, 1.1–2.4; p = .03), and impaired cognitive functioning (OR, 2.3; 95% CI, 1.5–3.6; p < .01). There was no evidence for independent effects of gender, histology, affected lobe, time since diagnosis, or employment status.Conclusions: Approximately one third of adult patients with high‐grade glioma may suffer from a clinically relevant common mental disorder, without notable disparity between the genders. In particular, clinicians should pay attention to possible comorbidities for cases in which patients exhibit compromised subjective cognitive function, are younger than 50 years, maintain a state of stable disease, or live alone.
Open AccessFrequency and clinical associations of common mental disorders in adults with high‐grade glioma—A multicenter study
Background: One third of adults with cancer suffer from common mental disorders in addition to their malignant disease. However, it is unknown whether this proportion is the same in patients who have brain tumors and which factors modulate the risk for psychiatric comorbidity.Methods: In a multicenter study, patients with high‐grade glioma at 13 neurooncology clinics were enrolled consecutively and interviewed with the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (SCID) to diagnose common mental disorders. Predictors of psychiatric comorbidity were investigated using binary logistic regression.Results: Six hundred ninety‐one patients were interviewed. The proportion of patients who had mental disorders was 31% (95% confidence interval [CI], 28%–35%). There was evidence for an association of psychiatric comorbidity with the following factors: younger age (odds ratio [OR], 1.9; 95% CI, 1.1–3.4; p = .04), stable disease versus complete remission (OR, 1.7; 95% CI, 1.1–2.8; p = .04), lower income (OR, 1.7; 95% CI, 1.0–2.8; p = .04), living alone (OR, 1.6; 95% CI, 1.0–2.6; p = .05), fatigue (OR, 1.6; 95% CI, 1.1–2.4; p = .03), and impaired cognitive functioning (OR, 2.3; 95% CI, 1.5–3.6; p < .01). There was no evidence for independent effects of gender, histology, affected lobe, time since diagnosis, or employment status.Conclusions: Approximately one third of adult patients with high‐grade glioma may suffer from a clinically relevant common mental disorder, without notable disparity between the genders. In particular, clinicians should pay attention to possible comorbidities for cases in which patients exhibit compromised subjective cognitive function, are younger than 50 years, maintain a state of stable disease, or live alone.
- Open Access
- 7 February 2024
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 167 (1) , 133-144
Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas
Background: Isocitrate dehydrogenase (IDH)1/2 wildtype (wt) astrocytomas formerly classified as WHO grade II or III have significantly shorter PFS and OS than IDH mutated WHO grade 2 and 3 gliomas leading to a classification as CNS WHO grade 4. It is the aim of this study to evaluate differences in the treatment-related clinical course of these tumors as they are largely unknown. Methods: Patients undergoing surgery (between 2016–2019 in six neurosurgical departments) for a histologically diagnosed WHO grade 2–3 IDH1/2-wt astrocytoma were retrospectively reviewed to assess progression free survival (PFS), overall survival (OS), and prognostic factors. Results: This multi-center study included 157 patients (mean age 58 years (20–87 years); with 36.9% females). The predominant histology was anaplastic astrocytoma WHO grade 3 (78.3%), followed by diffuse astrocytoma WHO grade 2 (21.7%). Gross total resection (GTR) was achieved in 37.6%, subtotal resection (STR) in 28.7%, and biopsy was performed in 33.8%. The median PFS (12.5 months) and OS (27.0 months) did not differ between WHO grades. Both, GTR and STR significantly increased PFS (P < 0.01) and OS (P < 0.001) compared to biopsy. Treatment according to Stupp protocol was not associated with longer OS or PFS compared to chemotherapy or radiotherapy alone. EGFR amplification (P = 0.014) and TERT-promotor mutation (P = 0.042) were associated with shortened OS. MGMT-promoter methylation had no influence on treatment response. Conclusions: WHO grade 2 and 3 IDH1/2 wt astrocytomas, treated according to the same treatment protocols, have a similar OS. Age, extent of resection, and strong EGFR expression were the most important treatment related prognostic factors.
- 7 February 2024
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 167 (1) , 133-144
Open AccessTreatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas
Background: Isocitrate dehydrogenase (IDH)1/2 wildtype (wt) astrocytomas formerly classified as WHO grade II or III have significantly shorter PFS and OS than IDH mutated WHO grade 2 and 3 gliomas leading to a classification as CNS WHO grade 4. It is the aim of this study to evaluate differences in the treatment-related clinical course of these tumors as they are largely unknown. Methods: Patients undergoing surgery (between 2016–2019 in six neurosurgical departments) for a histologically diagnosed WHO grade 2–3 IDH1/2-wt astrocytoma were retrospectively reviewed to assess progression free survival (PFS), overall survival (OS), and prognostic factors. Results: This multi-center study included 157 patients (mean age 58 years (20–87 years); with 36.9% females). The predominant histology was anaplastic astrocytoma WHO grade 3 (78.3%), followed by diffuse astrocytoma WHO grade 2 (21.7%). Gross total resection (GTR) was achieved in 37.6%, subtotal resection (STR) in 28.7%, and biopsy was performed in 33.8%. The median PFS (12.5 months) and OS (27.0 months) did not differ between WHO grades. Both, GTR and STR significantly increased PFS (P < 0.01) and OS (P < 0.001) compared to biopsy. Treatment according to Stupp protocol was not associated with longer OS or PFS compared to chemotherapy or radiotherapy alone. EGFR amplification (P = 0.014) and TERT-promotor mutation (P = 0.042) were associated with shortened OS. MGMT-promoter methylation had no influence on treatment response. Conclusions: WHO grade 2 and 3 IDH1/2 wt astrocytomas, treated according to the same treatment protocols, have a similar OS. Age, extent of resection, and strong EGFR expression were the most important treatment related prognostic factors.
- Open Access
Predictors of Neurological Worsening after Resection of Spinal Meningiomas
Background: Due to the slow-growing nature of spinal meningiomas, they are mostly asymptomatic for a long time, and become symptomatic after the compression of the spinal cord or nerve roots. The aim of this study was to identify predictors for a poor clinical outcome after the surgical resection of spinal meningiomas and thereby to allow a preoperative identification of high-risk spinal meningiomas. Methods: Data acquisition was conducted as a single-center retrospective analysis. From 1 January 2004 to 31 December 2019, 121 patients who underwent surgical resection of a spinal meningioma were reviewed. Clinical and radiological data (such as tumor size, location, occupation ratio of the spinal canal, and the degree of spinal cord compression) were assessed. The functional clinical findings of the patients were recorded using the Karnofsky Performance Score, modified McCormick scale, and Frankel scale preoperatively, at discharge, and 3–6 months after surgery. Results: The mean patient age was 66 ± 13 years. A total of 104 (86%) patients were female and 17 (14%) were male. The thoracic spine (68%) was the most common location, followed by the cervical (29%) and lumbar (3%) spine. Preoperatively, 11.7% of patients were categorized as McCormick 1, 35.8% as 2, 39.2% as 3, 11.7% as 4, and 1.7% as 5. The neurological function of the patients with a functional deficit prior to surgery improved in 46% of the patients, remained unchanged in 52%, and worsened in 2% at discharge. At early follow-up, the proportions were 54%, 28%, and 5%, respectively. Preoperative Frankel scale was a significant predictor of a postoperative deterioration. Patients with Frankel score A to C preoperatively had a 9.2 times higher chance of clinical deterioration postoperatively (OR = 9.16). We found that the Frankel scale weakly correlated with the degree of spinal cord compression. In this study, other radiological parameters, such as the degree of cord compression and spinal canal occupation ratio, did not show a significant effect on the outcome. Conclusions: Surgery of intraspinal meningiomas can be considered safe. Neurological function improves in a large proportion of patients after surgery. However, a relevant preoperative deficit according to the Frankel scale (grade A–C) was a significant predictor of a postoperative neurological deterioration.
Open AccessPredictors of Neurological Worsening after Resection of Spinal Meningiomas
Background: Due to the slow-growing nature of spinal meningiomas, they are mostly asymptomatic for a long time, and become symptomatic after the compression of the spinal cord or nerve roots. The aim of this study was to identify predictors for a poor clinical outcome after the surgical resection of spinal meningiomas and thereby to allow a preoperative identification of high-risk spinal meningiomas. Methods: Data acquisition was conducted as a single-center retrospective analysis. From 1 January 2004 to 31 December 2019, 121 patients who underwent surgical resection of a spinal meningioma were reviewed. Clinical and radiological data (such as tumor size, location, occupation ratio of the spinal canal, and the degree of spinal cord compression) were assessed. The functional clinical findings of the patients were recorded using the Karnofsky Performance Score, modified McCormick scale, and Frankel scale preoperatively, at discharge, and 3–6 months after surgery. Results: The mean patient age was 66 ± 13 years. A total of 104 (86%) patients were female and 17 (14%) were male. The thoracic spine (68%) was the most common location, followed by the cervical (29%) and lumbar (3%) spine. Preoperatively, 11.7% of patients were categorized as McCormick 1, 35.8% as 2, 39.2% as 3, 11.7% as 4, and 1.7% as 5. The neurological function of the patients with a functional deficit prior to surgery improved in 46% of the patients, remained unchanged in 52%, and worsened in 2% at discharge. At early follow-up, the proportions were 54%, 28%, and 5%, respectively. Preoperative Frankel scale was a significant predictor of a postoperative deterioration. Patients with Frankel score A to C preoperatively had a 9.2 times higher chance of clinical deterioration postoperatively (OR = 9.16). We found that the Frankel scale weakly correlated with the degree of spinal cord compression. In this study, other radiological parameters, such as the degree of cord compression and spinal canal occupation ratio, did not show a significant effect on the outcome. Conclusions: Surgery of intraspinal meningiomas can be considered safe. Neurological function improves in a large proportion of patients after surgery. However, a relevant preoperative deficit according to the Frankel scale (grade A–C) was a significant predictor of a postoperative neurological deterioration.
- Open Access
- 12 October 2022
- Published by Springer Nature in Neurosurgical Review
- Vol. 45 (6) , 3647-3655
Analysis of PMMA versus CaP titanium-enhanced implants for cranioplasty after decompressive craniectomy: a retrospective observational cohort study
Numerous materials of implants used for cranioplasty after decompressive craniectomy (DC) have been investigated to meet certain demanded key features, such as stability, applicability, and biocompatibility. We aimed to evaluate the feasibility and safety of biocompatible calcium-phosphate (CaP) implants for cranioplasty compared to polymethylmethacrylate (PMMA) implants. In this retrospective observational cohort study, the medical records of all patients who underwent cranioplasty between January 1st, 2015, and January 1st, 2022, were reviewed. Demographic, clinical, and diagnostic data were collected. Eighty-two consecutive patients with a mean age of 52 years (range 22–72 years) who received either a PMMA (43/82; 52.4%) or CaP (39/82; 47.6%) cranial implant after DC were included in the study. Indications for DC were equally distributed in both groups. Time from DC to cranioplasty was 143.8 ± 17.5 days (PMMA) versus 98.5 ± 10.4 days (CaP). The mean follow-up period was 34.9 ± 27.1 months. Postoperative complications occurred in 13 patients with PMMA and 6 in those with CaP implants (13/43 [30.2%] vs. 6/39 [15.4%]; p = 0.115). Revision surgery with implant removal was necessary for 9 PMMA patients and in 1 with a CaP implant (9/43 [20.9%] vs. 1/39 [2.6%]; p = 0.0336); 6 PMMA implants were removed due to surgical site infection (SSI) (PMMA 6/43 [14%] vs. CaP 0/39 [0%]; p = 0.012). In this study, a biocompatible CaP implant seems to be superior to a PMMA implant in terms of SSI and postoperative complications. The absence of SSI supports the idea of the biocompatible implant material with its ability for osseointegration.
- 12 October 2022
- Published by Springer Nature in Neurosurgical Review
- Vol. 45 (6) , 3647-3655
Open AccessAnalysis of PMMA versus CaP titanium-enhanced implants for cranioplasty after decompressive craniectomy: a retrospective observational cohort study
Numerous materials of implants used for cranioplasty after decompressive craniectomy (DC) have been investigated to meet certain demanded key features, such as stability, applicability, and biocompatibility. We aimed to evaluate the feasibility and safety of biocompatible calcium-phosphate (CaP) implants for cranioplasty compared to polymethylmethacrylate (PMMA) implants. In this retrospective observational cohort study, the medical records of all patients who underwent cranioplasty between January 1st, 2015, and January 1st, 2022, were reviewed. Demographic, clinical, and diagnostic data were collected. Eighty-two consecutive patients with a mean age of 52 years (range 22–72 years) who received either a PMMA (43/82; 52.4%) or CaP (39/82; 47.6%) cranial implant after DC were included in the study. Indications for DC were equally distributed in both groups. Time from DC to cranioplasty was 143.8 ± 17.5 days (PMMA) versus 98.5 ± 10.4 days (CaP). The mean follow-up period was 34.9 ± 27.1 months. Postoperative complications occurred in 13 patients with PMMA and 6 in those with CaP implants (13/43 [30.2%] vs. 6/39 [15.4%]; p = 0.115). Revision surgery with implant removal was necessary for 9 PMMA patients and in 1 with a CaP implant (9/43 [20.9%] vs. 1/39 [2.6%]; p = 0.0336); 6 PMMA implants were removed due to surgical site infection (SSI) (PMMA 6/43 [14%] vs. CaP 0/39 [0%]; p = 0.012). In this study, a biocompatible CaP implant seems to be superior to a PMMA implant in terms of SSI and postoperative complications. The absence of SSI supports the idea of the biocompatible implant material with its ability for osseointegration.
- Open Access
Impact of Sarcopenia and Bone Mineral Density on Implant Failure after Dorsal Instrumentation in Patients with Osteoporotic Vertebral Fractures
Background and Objectives: Age-related loss of bone and muscle mass are signs of frailty and are associated with an increased risk of falls and consecutive vertebral fractures. Management often necessitates fusion surgery. We determined the impacts of sarcopenia and bone density on implant failures (IFs) and complications in patients with spondylodesis due to osteoporotic vertebral fractures (OVFs). Materials and Methods: Patients diagnosed with an OVF according to the osteoporotic fracture classification (OF) undergoing spinal instrumentation surgery between 2011 and 2020 were included in our study. The skeletal muscle area (SMA) was measured at the third lumbar vertebra (L3) level using axial CT images. SMA z-scores were calculated for the optimal height and body mass index (BMI) adjustment (zSMAHT). The loss of muscle function was assessed via measurement of myosteatosis (skeletal muscle radiodensity, SMD) using axial CT scans. The bone mineral density (BMD) was determined at L3 in Hounsfield units (HU). Results: A total of 68 patients with OVFs underwent instrumentation in 244 segments (mean age 73.7 ± 7.9 years, 60.3% female). The median time of follow-up was 14.1 ± 15.5 months. Sarcopenia was detected in 28 patients (47.1%), myosteatosis in 45 patients (66.2%), and osteoporosis in 49 patients (72%). The presence of sarcopenia was independent of chronological age (p = 0.77) but correlated with BMI (p = 0.005). The zSMAHT was significantly lower in patients suffering from an IF (p = 0.0092). Sarcopenia (OR 4.511, 95% CI 1.459–13.04, p = 0.0092) and osteoporosis (OR 9.50, 95% CI 1.497 to 104.7, p = 0.014) increased the likelihood of an IF. Using multivariate analysis revealed that the zSMAHT (p = 0.0057) and BMD (p = 0.0041) were significantly related to IF occurrence. Conclusion: Herein, we established sarcopenic obesity as the main determinant for the occurrence of an IF after instrumentation for OVF. To a lesser degree, osteoporosis was associated with impaired implant longevity. Therefore, measuring the SMA and BMD using an axial CT of the lumbar spine might help to prevent an IF in spinal fusion surgery via early detection and treatment of sarcopenia and osteoporosis.
Open AccessImpact of Sarcopenia and Bone Mineral Density on Implant Failure after Dorsal Instrumentation in Patients with Osteoporotic Vertebral Fractures
Background and Objectives: Age-related loss of bone and muscle mass are signs of frailty and are associated with an increased risk of falls and consecutive vertebral fractures. Management often necessitates fusion surgery. We determined the impacts of sarcopenia and bone density on implant failures (IFs) and complications in patients with spondylodesis due to osteoporotic vertebral fractures (OVFs). Materials and Methods: Patients diagnosed with an OVF according to the osteoporotic fracture classification (OF) undergoing spinal instrumentation surgery between 2011 and 2020 were included in our study. The skeletal muscle area (SMA) was measured at the third lumbar vertebra (L3) level using axial CT images. SMA z-scores were calculated for the optimal height and body mass index (BMI) adjustment (zSMAHT). The loss of muscle function was assessed via measurement of myosteatosis (skeletal muscle radiodensity, SMD) using axial CT scans. The bone mineral density (BMD) was determined at L3 in Hounsfield units (HU). Results: A total of 68 patients with OVFs underwent instrumentation in 244 segments (mean age 73.7 ± 7.9 years, 60.3% female). The median time of follow-up was 14.1 ± 15.5 months. Sarcopenia was detected in 28 patients (47.1%), myosteatosis in 45 patients (66.2%), and osteoporosis in 49 patients (72%). The presence of sarcopenia was independent of chronological age (p = 0.77) but correlated with BMI (p = 0.005). The zSMAHT was significantly lower in patients suffering from an IF (p = 0.0092). Sarcopenia (OR 4.511, 95% CI 1.459–13.04, p = 0.0092) and osteoporosis (OR 9.50, 95% CI 1.497 to 104.7, p = 0.014) increased the likelihood of an IF. Using multivariate analysis revealed that the zSMAHT (p = 0.0057) and BMD (p = 0.0041) were significantly related to IF occurrence. Conclusion: Herein, we established sarcopenic obesity as the main determinant for the occurrence of an IF after instrumentation for OVF. To a lesser degree, osteoporosis was associated with impaired implant longevity. Therefore, measuring the SMA and BMD using an axial CT of the lumbar spine might help to prevent an IF in spinal fusion surgery via early detection and treatment of sarcopenia and osteoporosis.
- Open Access
- 18 March 2022
- Published by Springer Nature in Research Square
A Comparative Analysis of PMMA Versus CaP Titanium-Enhanced Implants for Cranioplasty After Decompressive Craniectomy
Objective Numerous materials used for cranioplasty (CP) after decompressive craniectomy (DC) have been investigated to meet certain demanded key features, such as stability, surgical applicability, and biocompatibility. We aimed to evaluate the feasibility and safety of biocompatible calcium-phosphate (CaP) titanium-enhanced implants for CP compared to polymethylmethacrylate (PMMA) implants. Methods The medical records of all patients who underwent CP between January 1st, 2015, and January 1st, 2022, were reviewed. Demographic, clinical, and diagnostic data were collected before and after the CP. Results 82 consecutive patients with a mean age of 52 years (range 22–72 years) who received either a PMMA (43) or CaP (39) cranial implant after DC were included in our study. Indications for DC were equally distributed in both groups, including middle cerebral artery infarction (35 cases), traumatic brain injury (24 cases), subarachnoid hemorrhage (15 cases), intracerebral hemorrhage (3 cases). Time from DC to CP was similar in both groups 143.8 ± 17.46 days (PMMA) versus 98.46 ± 10.37 days (CaP). The mean follow-up period was 34.9 ± 27.1 months. 13 procedure-related complications occurred in patients with PMMA, 6 in those with CaP implants (p = 0.126). Revision surgery with implant removal was necessary for 9 patients with PMMA implants, one in those with CaP implants. The probability of implant removal was significantly higher in the PMMA implant group (p = 0.039). Conclusions In the present study, a titanium-enhanced biocompatible CaP implant proved superior to a PMMA implant in terms of surgical site infection. This supports the idea of the biocompatible implant material with its ability for tissue integration.
- 18 March 2022
- Published by Springer Nature in Research Square
Open AccessA Comparative Analysis of PMMA Versus CaP Titanium-Enhanced Implants for Cranioplasty After Decompressive Craniectomy
Objective Numerous materials used for cranioplasty (CP) after decompressive craniectomy (DC) have been investigated to meet certain demanded key features, such as stability, surgical applicability, and biocompatibility. We aimed to evaluate the feasibility and safety of biocompatible calcium-phosphate (CaP) titanium-enhanced implants for CP compared to polymethylmethacrylate (PMMA) implants. Methods The medical records of all patients who underwent CP between January 1st, 2015, and January 1st, 2022, were reviewed. Demographic, clinical, and diagnostic data were collected before and after the CP. Results 82 consecutive patients with a mean age of 52 years (range 22–72 years) who received either a PMMA (43) or CaP (39) cranial implant after DC were included in our study. Indications for DC were equally distributed in both groups, including middle cerebral artery infarction (35 cases), traumatic brain injury (24 cases), subarachnoid hemorrhage (15 cases), intracerebral hemorrhage (3 cases). Time from DC to CP was similar in both groups 143.8 ± 17.46 days (PMMA) versus 98.46 ± 10.37 days (CaP). The mean follow-up period was 34.9 ± 27.1 months. 13 procedure-related complications occurred in patients with PMMA, 6 in those with CaP implants (p = 0.126). Revision surgery with implant removal was necessary for 9 patients with PMMA implants, one in those with CaP implants. The probability of implant removal was significantly higher in the PMMA implant group (p = 0.039). Conclusions In the present study, a titanium-enhanced biocompatible CaP implant proved superior to a PMMA implant in terms of surgical site infection. This supports the idea of the biocompatible implant material with its ability for tissue integration.
- Open Access
- 21 February 2022
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 8, 791427
Evaluation of 3D Robotic-Guided Exoscopic Visualization in Microneurosurgery
Objective: The three-dimensional (3D) exoscope is a novel apparatus introduced in recent years. Although an operating microscope (OM) is customarily used, this novel application offers several advantages. Therefore, this study aimed to determine the feasibility of deploying a robotic-guided 3D-exoscope for microneurosurgery and gauge its subsequent performance.Methods: The use of a 3D exoscope was compared with that of OM during 16 surgical procedures. Postoperatively, surgeons completed an eight-item Likert-scale satisfaction survey. As a second step, a predefined surgical task was then undertaken by surgeons with varying levels of experience, assessing the time entailed. Two questionnaires, the satisfaction survey and NASA task load index (NASA-TLX), were administered.Results: During routine procedures, the exoscope proved superior in magnification and ergonomic maintenance, showing inferior image contrast, quality, and illumination. It again ranked higher in magnification and ergonomic maintenance during the suturing task, and the OM excelled in treatment satisfaction and stereoscopic orientation. Workload assessment using the NASA-TLX revealed no difference by modality in the pairwise analysis of all components. At varying levels of experience, beginners bear a significantly higher burden in all principle components than mid-level and expert participants (p = 0.0018). Completion times for the suturing task did not differ (p = 0.22).Conclusion: The quality of visualization by 3D exoscope seems adequate for treatment and its ergonomic benefit is superior to that of OM. Although experienced surgeons performed a surgical simulation faster under the OM, no difference was evident in NASA-TLX surveys. The 3D exoscope is an excellent alternative to the OM.
- 21 February 2022
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 8, 791427
Open AccessEvaluation of 3D Robotic-Guided Exoscopic Visualization in Microneurosurgery
Objective: The three-dimensional (3D) exoscope is a novel apparatus introduced in recent years. Although an operating microscope (OM) is customarily used, this novel application offers several advantages. Therefore, this study aimed to determine the feasibility of deploying a robotic-guided 3D-exoscope for microneurosurgery and gauge its subsequent performance.Methods: The use of a 3D exoscope was compared with that of OM during 16 surgical procedures. Postoperatively, surgeons completed an eight-item Likert-scale satisfaction survey. As a second step, a predefined surgical task was then undertaken by surgeons with varying levels of experience, assessing the time entailed. Two questionnaires, the satisfaction survey and NASA task load index (NASA-TLX), were administered.Results: During routine procedures, the exoscope proved superior in magnification and ergonomic maintenance, showing inferior image contrast, quality, and illumination. It again ranked higher in magnification and ergonomic maintenance during the suturing task, and the OM excelled in treatment satisfaction and stereoscopic orientation. Workload assessment using the NASA-TLX revealed no difference by modality in the pairwise analysis of all components. At varying levels of experience, beginners bear a significantly higher burden in all principle components than mid-level and expert participants (p = 0.0018). Completion times for the suturing task did not differ (p = 0.22).Conclusion: The quality of visualization by 3D exoscope seems adequate for treatment and its ergonomic benefit is superior to that of OM. Although experienced surgeons performed a surgical simulation faster under the OM, no difference was evident in NASA-TLX surveys. The 3D exoscope is an excellent alternative to the OM.
- Open Access
Beyond Glioma: The Utility of Radiomic Analysis for Non-Glial Intracranial Tumors
The field of radiomics is rapidly expanding and gaining a valuable role in neuro-oncology. The possibilities related to the use of radiomic analysis, such as distinguishing types of malignancies, predicting tumor grade, determining the presence of particular molecular markers, consistency, therapy response, and prognosis, can considerably influence decision-making in medicine in the near future. Even though the main focus of radiomic analyses has been on glial CNS tumors, studies on other intracranial tumors have shown encouraging results. Therefore, as the main focus of this review, we performed an analysis of publications on PubMed and Web of Science databases, focusing on radiomics in CNS metastases, lymphoma, meningioma, medulloblastoma, and pituitary tumors.
Open AccessBeyond Glioma: The Utility of Radiomic Analysis for Non-Glial Intracranial Tumors
The field of radiomics is rapidly expanding and gaining a valuable role in neuro-oncology. The possibilities related to the use of radiomic analysis, such as distinguishing types of malignancies, predicting tumor grade, determining the presence of particular molecular markers, consistency, therapy response, and prognosis, can considerably influence decision-making in medicine in the near future. Even though the main focus of radiomic analyses has been on glial CNS tumors, studies on other intracranial tumors have shown encouraging results. Therefore, as the main focus of this review, we performed an analysis of publications on PubMed and Web of Science databases, focusing on radiomics in CNS metastases, lymphoma, meningioma, medulloblastoma, and pituitary tumors.